Moreover, to these biomarkers, other biomarkers are being investigated in NSCLC, such as mutations in the KRAS gene, fusion of the RET gene, and expression of ROS1 and BRAF, among others. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.